Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Liabilities and Shareholders Equity: 2019-2022

Historic Liabilities and Shareholders Equity for ADC Therapeutics (ADCT) over the last 3 years, with Dec 2022 value amounting to $490.9 million.

  • ADC Therapeutics' Liabilities and Shareholders Equity fell 12.20% to $466.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $1.9 billion, marking a year-over-year increase of 18.23%. This contributed to the annual value of $490.9 million for FY2022, which is 79330.62% up from last year.
  • Latest data reveals that ADC Therapeutics reported Liabilities and Shareholders Equity of $490.9 million as of FY2022, which was up 79,330.62% from $617,972 recorded in FY2021.
  • Over the past 5 years, ADC Therapeutics' Liabilities and Shareholders Equity peaked at $490.9 million during FY2022, and registered a low of $137,682 during FY2019.
  • Over the past 2 years, ADC Therapeutics' median Liabilities and Shareholders Equity value was $245.7 million (recorded in 2021), while the average stood at $245.7 million.
  • Data for ADC Therapeutics' Liabilities and Shareholders Equity shows a peak YoY soared of 79,330.62% (in 2022) over the last 5 years.
  • Yearly analysis of 3 years shows ADC Therapeutics' Liabilities and Shareholders Equity stood at $137,682 in 2019, then reached $617,972 in 2021, then spiked by 79,330.62% to $490.9 million in 2022.